Effect of olapalil on maintenance therapy and serum tumor markers in patients with advanced ovarian cancer
Objective To explore the effect of Olapalil on maintenance therapy and serum tumor markers in patients with advanced ovarian cancer.Methods The clinical data of 68 patients with advanced ovarian cancer who received treatment in our hospital from January 2019 to January 2020 were retrospectively analyzed,according to different treatment methods,they were divided into observation group(32 cases)and control group(36 cases).The control group was treated with bevacizumab maintenance therapy,and the observation group was treated with olapalil maintenance therapy on the basis of the control group,the treatment lasted for 12 cycles.The changes of carbohydrate antigen(CA)125,CA199,human epididymal protein 4(HE4),alpha-fetoprotein(AFP),T lymphocyte subsets CD3+,CD4+,CD4+/CD8+before and after treatment were compared between the two groups,and the prognosis and incidence of adverse reactions were compared.Results The CA125,CA199,HE4 and APF in the observation group were lower than the control group,with statistical significance(P＜0.05);the CD3+,CD4+,CD4+/CD8+in the observation group were higher than the control group,with statistical significance(P＜0.05);Follow-up to December 2022,the progression-free survival(PFS)of the observation group was significantly longer than that of the control group,with statistical significance(P＜0.05);The incidence of blood diseases in the observation group was significantly higher than the control group,with statistical significance(P＜0.05).Conclusion Olaparil plays an obvious role in the maintenance treatment of advanced ovarian cancer patients,which can reduce the level of serum tumor markers and prolong the PFS,and is worthy of clinical promotion.
NETL
NSTL
万方数据
